Castellum, Inc. Announces Signing of Non-Binding LOI for East Coast Government Contractor Castellum, Inc. (NYSE-American: CTM), a cybersecurity, electronic warfare,...
Dylan Bates, Chief Executive Officer Salt Dental Collective announced that Dylan Bates has been appointed as the new Chief Executive...
BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical...
Real-world study compares diabetic gastroparesis patient utilization of healthcare resources before and after initiation of GIMOTISOLANA BEACH, Calif., Jan. 18,...
TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader...
Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary...
Live video webcast on Thursday, January 19th at 12:00 PM ETDURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc....
SIOUX FALLS, S.D., Jan. 18, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel...
Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive and entrepreneur, appointed Chief Executive Officer Carin Rollins, Hinge Bio co-founder, becomes...
Reports preliminary fourth quarter 2022 revenue of $14.9 millionAnnounces full-year and first-quarter 2023 financial guidanceWINTER SPRINGS, Fla., Jan. 18, 2023...
-- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023...
Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in EuropeSAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- aTyr...
Eight distinguished business and community leaders joined the MUHC Foundation’s Board of Directors in 2022. The MUHC Foundation welcomes new...
Wound care professionals across multiple specialties to support strategic alignment of patient, payor, and provider goalsFRAMINGHAM, Mass., Jan. 18, 2023...
Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent guidance rangeCash position as of...
KemPharm advancing multicenter Phase 2 clinical trial investigating the efficacy and safety of KP1077 for the treatment of idiopathic hypersomnia...
The Company has already secured approvals from Ethics Committee and Israeli Ministry of Health for the Company's study with its proprietary SCI-210 treatment TEL AVIV, Israel, Jan. 18,...
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s...
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin...
Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE)...